Latest From PanOptica Inc.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Emerging Company Profile: Inhibitors of VEGF-A alternative mRNA splicing could deliver a step-change in the treatment of retinal eye diseases, hopes UK start-up Exonate.
Private Company Edition: Life science firms in J&J's JLabs incubators have raised $9.4bn to date from deals and financings, including five IPOs. Also, October brings a wide range of new equity and VC financings.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Recent Financings Of Private Companies column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced March through April 2014.
- Specialty Pharmaceuticals
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- PanOptica Inc.
- Senior Management
Paul Chaney, Pres. & CEO
Martin Wax, MD, CMO & EVP, R&D
Lori Forrest, Exec. Dir., Fin. & Controller
- Contact Info
Phone: (908) 766-2202
150 Morristown Rd.
Bernardsville, NJ 07924-2626
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.